The recently published peer-review "PEARL" trial appeared to show three things: 1) it is safe for humans (doses were 5mg in one group; 10mg in another). 2) efficacy was indeterminate. 3) The way in which it is compounded (tablet, capsule, etc.) greatly affects dosage and absorption. The endpoint of the PEARL trial was actually "safety," and not "efficacy." Clearly, more randomized clinical trials are needed.
How to prevent Rapamycin from downregulating the very HIF-1, Wnt/Beta-catenin, IGF-1R, AR and TERT pathways that are needed for good stem cells' recruitment, proliferation, migration and adhesion?